Skip to content

Biting the hand that feeds IT

The Register ®

Science:


Related Whitepapers

[Print][Mobile][Alerts]

Drug trial guinea pig faces new medical battle

Diagnosed with cancer

Published Tuesday 8th August 2006 08:45 GMT

One of the victims of the disastrous drug trial at Northwick Park Hospital earlier this year says he has now been diagnosed with the early stages of cancer.

The disease is attacking New Zealander David Oakley's lymphatic system, part of the immune system. He told The BBC: "It's an early sign of cancer. The best I could actually get was that if we catch it early enough it is treatable."

Six men who were hospitalised by TGN1412, an experimental treatment designed to combat immune conditions such as arthritis and multiple sclerosis, along with certain forms of leukaemia.

But instead of damping down the immune system, the compound over-stimulated it, causing the massive swelling which prompted one woman to describe her boyfriend as looking like "The Elephant Man".

After the tests went badly wrong, the men were warned they could face developing cancer, though there is no proof the trial caused Mr Oakley's condition.

An inquiry by the Medicines and Healthcare products Regulatory Authority found the trial operator Parexel had not liased properly with the drug's German developers TeGenero.

The volunteers' lawyers are currently seeking greater compensation than the initial £5,000 they were offered in April. ®

Track this type of story as a custom Atom/RSS feed or by email.
Previous Article Next Article
whitepaper title

Making Green IT a Reality

Customer Perspectives on the Impact of Storage Vendor Decisions on Power, Cooling, & Space in Enterprise Data Centers.
whitepaper title

Enabling the Data Center Metamorphosis

This independent analyst paper gives real world advice on transforming your datacenter into a streamlined, dynamic, liquid engine capable of handling growth..
Whitepapers Jobs

Top 20 storiesAll The Week’s HeadlinesArchiveSearch